KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Recursion Pharmaceuticals (RXRX) EBT Margin (2020 - 2025)

Recursion Pharmaceuticals' EBT Margin history spans 6 years, with the latest figure at 304.19% for Q4 2025.

  • For Q4 2025, EBT Margin rose 363112.0% year-over-year to 304.19%; the TTM value through Dec 2025 reached 863.53%, down 7360.0%, while the annual FY2025 figure was 863.53%, 7360.0% down from the prior year.
  • EBT Margin reached 304.19% in Q4 2025 per RXRX's latest filing, up from 3135.27% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 304.19% in Q4 2025 to a low of 3935.31% in Q4 2024.
  • Average EBT Margin over 5 years is 1219.62%, with a median of 887.14% recorded in 2023.
  • Peak YoY movement for EBT Margin: soared 2938181bps in 2021, then plummeted -304413bps in 2024.
  • A 5-year view of EBT Margin shows it stood at 2564.55% in 2021, then skyrocketed by 83bps to 445.91% in 2022, then crashed by -100bps to 891.18% in 2023, then tumbled by -342bps to 3935.31% in 2024, then surged by 92bps to 304.19% in 2025.
  • Per Business Quant, the three most recent readings for RXRX's EBT Margin are 304.19% (Q4 2025), 3135.27% (Q3 2025), and 894.23% (Q2 2025).